Gail DeRaffele

1.5k total citations
19 papers, 1.1k citations indexed

About

Gail DeRaffele is a scholar working on Immunology, Oncology and Genetics. According to data from OpenAlex, Gail DeRaffele has authored 19 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 13 papers in Oncology and 11 papers in Genetics. Recurrent topics in Gail DeRaffele's work include Immunotherapy and Immune Responses (14 papers), Virus-based gene therapy research (11 papers) and CAR-T cell therapy research (10 papers). Gail DeRaffele is often cited by papers focused on Immunotherapy and Immune Responses (14 papers), Virus-based gene therapy research (11 papers) and CAR-T cell therapy research (10 papers). Gail DeRaffele collaborates with scholars based in United States, United Kingdom and Egypt. Gail DeRaffele's co-authors include Howard L. Kaufman, Seunghee Kim‐Schulze, Josephine Mitcham, Dae Won Kim, Rob Coffin, Dorota Moroziewicz, Charles Hesdorffer, Ken Cheung, G Cesana and Seth A. Cohen and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Urology.

In The Last Decade

Gail DeRaffele

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gail DeRaffele United States 12 785 624 392 336 98 19 1.1k
Jacob Ricca United States 8 583 0.7× 392 0.6× 340 0.9× 297 0.9× 84 0.9× 12 933
Marti Goemann United States 4 713 0.9× 611 1.0× 418 1.1× 438 1.3× 117 1.2× 6 1.1k
Wayne Aldrich United States 19 419 0.5× 590 0.9× 262 0.7× 501 1.5× 54 0.6× 46 1.1k
Doris Coleman United States 8 771 1.0× 1.4k 2.2× 257 0.7× 883 2.6× 71 0.7× 9 1.7k
Engin Gürlevik Germany 17 564 0.7× 417 0.7× 313 0.8× 460 1.4× 46 0.5× 21 1.1k
Kathleen M. Haines United States 10 722 0.9× 394 0.6× 253 0.6× 338 1.0× 40 0.4× 15 1.1k
Bangxing Hong United States 18 445 0.6× 578 0.9× 190 0.5× 344 1.0× 45 0.5× 37 1.0k
William Shingler United Kingdom 13 380 0.5× 435 0.7× 149 0.4× 191 0.6× 116 1.2× 26 697
Pin-Yi Wang United States 14 331 0.4× 257 0.4× 327 0.8× 258 0.8× 38 0.4× 32 792
C H Delgado United States 8 840 1.1× 1.5k 2.4× 251 0.6× 755 2.2× 36 0.4× 8 1.9k

Countries citing papers authored by Gail DeRaffele

Since Specialization
Citations

This map shows the geographic impact of Gail DeRaffele's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gail DeRaffele with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gail DeRaffele more than expected).

Fields of papers citing papers by Gail DeRaffele

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gail DeRaffele. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gail DeRaffele. The network helps show where Gail DeRaffele may publish in the future.

Co-authorship network of co-authors of Gail DeRaffele

This figure shows the co-authorship network connecting the top 25 collaborators of Gail DeRaffele. A scholar is included among the top collaborators of Gail DeRaffele based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gail DeRaffele. Gail DeRaffele is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Kaufman, Howard L., et al.. (2014). Results of a Randomized Phase I Gene Therapy Clinical Trial of Nononcolytic Fowlpox Viruses Encoding T Cell Costimulatory Molecules. Human Gene Therapy. 25(5). 452–460. 12 indexed citations
2.
Kaufman, Howard L., Bret Taback, William H. Sherman, et al.. (2009). Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Journal of Translational Medicine. 7(1). 2–2. 55 indexed citations
3.
Kaufman, Howard L., Dae Won Kim, Gail DeRaffele, et al.. (2009). Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma. Annals of Surgical Oncology. 17(3). 718–730. 408 indexed citations
4.
Sabatino, Marianna, Seunghee Kim‐Schulze, Monica C. Panelli, et al.. (2009). Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy. Journal of Clinical Oncology. 27(16). 2645–2652. 132 indexed citations
5.
Kaufman, Howard L., Seunghee Kim‐Schulze, Dorota Moroziewicz, et al.. (2008). Correlation of effector and regulatory T cell responses with clinical outcome in metastatic renal cell carcinoma patients treated with MVA-5T4 vaccine and high-dose interleukin-2. Journal of Clinical Oncology. 26(15_suppl). 3004–3004. 1 indexed citations
6.
Kaufman, Howard L., Seunghee Kim‐Schulze, Kelledy Manson, et al.. (2007). Poxvirus-based vaccine therapy for patients with advanced pancreatic cancer. Journal of Translational Medicine. 5(1). 60–60. 84 indexed citations
7.
Kim‐Schulze, Seunghee, Gail DeRaffele, Josephine Mitcham, et al.. (2007). P239. Journal of Surgical Research. 137(2). 327–327. 1 indexed citations
8.
Kaufman, Howard L., Seth M. Cohen, Ken Cheung, et al.. (2006). Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors. Human Gene Therapy. 17(2). 239–244. 52 indexed citations
9.
Kaufman, Howard L., Seth M. Cohen, Kmc Cheung, et al.. (2006). Local Delivery of Vaccinia Virus Expressing Multiple Costimulatory Molecules for the Treatment of Established Tumors. Human Gene Therapy. 0(0). 4070844593–4070844593. 1 indexed citations
10.
Cesana, G, Gail DeRaffele, Seth A. Cohen, et al.. (2006). Characterization of CD4+CD25+ Regulatory T Cells in Patients Treated With High-Dose Interleukin-2 for Metastatic Melanoma or Renal Cell Carcinoma. Journal of Clinical Oncology. 24(7). 1169–1177. 275 indexed citations
11.
Kaufman, Howard L., Gail DeRaffele, Josephine Mitcham, et al.. (2006). A phase I clinical trial of MVA expressing 5T4 and high-dose interleukin-2 (IL-2) for metastatic renal cell carcinoma. Journal of Clinical Oncology. 24(18_suppl). 12500–12500. 5 indexed citations
12.
13.
Kaufman, Howard L., et al.. (2005). Panniculitis after vaccination against CEA and MUC1 in a patient with pancreatic cancer. The Lancet Oncology. 6(1). 62–63. 5 indexed citations
14.
Komenaka, Ian K., et al.. (2005). The contralateral sentinel node.. PubMed. 48(5). 416–7. 2 indexed citations
15.
DeRaffele, Gail, Josephine Mitcham, Dorota Moroziewicz, et al.. (2004). Manipulating the local tumor microenvironment with vaccinia virus expressing costimulatory molecules for the treatment of melanoma. Journal of Clinical Oncology. 22(14_suppl). 7504–7504. 1 indexed citations
16.
Lee, Christopher S.D., et al.. (2003). Management of metastatic malignant melanoma of the bladder. Urology. 62(2). 351–351. 21 indexed citations
17.
Kaufman, Howard L., Kenneth Cheung, Heidi Hörig, et al.. (2003). Intra-Lesional rF-B7.1 Versus rF-TRICOM Vaccine in the Treatment of Metastatic Cancer. Human Gene Therapy. 14(8). 803–827. 11 indexed citations
18.
Soni, Sandeep, et al.. (2002). Treatment of Pediatric Ocular Melanoma With High-Dose Interleukin-2 and Thalidomide. Journal of Pediatric Hematology/Oncology. 24(6). 488–491. 28 indexed citations
19.
Kaufman, Howard L., et al.. (2001). A Phase I Trial of Intralesional rV-Tricom Vaccine in the Treatment of Malignant Melanoma. Human Gene Therapy. 12(11). 1459–1480. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob Ricca Breakdown of academic impact, for papers by Marti Goemann Breakdown of academic impact, for papers by Wayne Aldrich Breakdown of academic impact, for papers by Doris Coleman Breakdown of academic impact, for papers by Engin Gürlevik Breakdown of academic impact, for papers by Kathleen M. Haines Breakdown of academic impact, for papers by Bangxing Hong Breakdown of academic impact, for papers by William Shingler Breakdown of academic impact, for papers by Pin-Yi Wang Breakdown of academic impact, for papers by C H Delgado
Rankless by CCL
2026